Director at Gavi, The Vaccine Alliance
- Availability of supply following US FDA EUA (Food and Drug Administration Emergency Use Authorisation), volume commitment updates and vaccine manufacturers’ ability to scale up supply
- Review of various go-to-market and vaccine allocation strategies
- Supply chain capacity, role of centralised or government entities and remaining logistical bottlenecks
- Timelines for mass-scale immunisation by region and outlook for herd immunity 5. Commercial opportunity for the industry
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.